VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Given Average Recommendation of “Reduce” by Brokerages

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) has been assigned an average recommendation of “Reduce” from the five research firms that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and four have issued a hold rating on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $0.95.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of VistaGen Therapeutics in a research note on Monday, August 31st.

VistaGen Therapeutics Stock Up 1.0%

VistaGen Therapeutics stock traded up $0.00 during midday trading on Friday, hitting $0.24. 10,146 shares of the stock were exchanged, compared to its average volume of 1,976,247. The company has a fifty day simple moving average of $0.25 and a two-hundred day simple moving average of $0.46. VistaGen Therapeutics has a 52 week low of $0.20 and a 52 week high of $5.14. The stock has a market capitalization of $10.47 million, a PE ratio of -0.14 and a beta of 0.39.

VistaGen Therapeutics (NASDAQ:VTGN) last issued its earnings results on Friday, August 14th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.06. The firm had revenue of $1.48 million during the quarter, compared to the consensus estimate of $0.50 million. VistaGen Therapeutics had a negative net margin of 2,702.64% and a negative return on equity of 152.59%. As a group, equities research analysts anticipate that VistaGen Therapeutics will post -1.45 EPS for the current fiscal year.

Institutional Trading of VistaGen Therapeutics

Hedge funds have recently bought and sold shares of the stock. Seven Fleet Capital Management LP bought a new stake in shares of VistaGen Therapeutics during the fourth quarter worth $42,000. AdvisorShares Investments LLC boosted its stake in VistaGen Therapeutics by 20.9% in the 4th quarter. AdvisorShares Investments LLC now owns 250,188 shares of the company’s stock worth $166,000 after purchasing an additional 43,190 shares during the period. Renaissance Technologies LLC boosted its stake in VistaGen Therapeutics by 81.2% in the 1st quarter. Renaissance Technologies LLC now owns 291,300 shares of the company’s stock worth $166,000 after purchasing an additional 130,509 shares during the period. BlackRock Inc. bought a new position in VistaGen Therapeutics during the 2nd quarter worth about $78,000. Finally, ADAR1 Capital Management LLC bought a new position in VistaGen Therapeutics during the 2nd quarter worth about $79,000. 78.39% of the stock is currently owned by institutional investors and hedge funds.

About VistaGen Therapeutics

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.